Using Tocilizumab in Sars COV-2 Dısease: Case Report

Author : -Elmas Uysal, Işıl Özkoçak Turan
Number of pages : 325-327


Coronavirus 19 (COVID-19) may cause a cytokine release syndrome inducing the severity of the disease. Various immune modulating agents are suggested due to the lack of definitive treatment and vaccine. In this case report, we aimed to share the clinical course of a Covid 19 patient who was given tocilizumab (TCZ) for severe ARDS on the 5th day of hospitalization. Although, the patient was extubated 12 days after TCZ treatment with a rapid recovery, we believe that more cases are needed to determine the efficiency and timing of TCZ treatment.


COVID-19 disease, IL-6, Tocilizumab

Read: 218

Download: 71